Nykode Therapeutics AS (OSL:NYKD)
kr 3.256 -0.034 (-1.03%) Market Cap: 1.07 Bil Enterprise Value: -265.37 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 46/100

Q3 2024 Nykode Therapeutics ASA Earnings Call Transcript

Nov 27, 2024 / 07:00AM GMT
Release Date Price: kr2.83 (+5.05%)
Operator

Greetings, and welcome to the Nykode Therapeutics third-quarter 2024 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to your host, CEO, Michael Engsig. Please go ahead.

Michael Engsig;Martin Nicklasson
Nykode Therapeutics ASA - Chief Executive Officer;Nykode

Thank you very much, Kevin, and a warm welcome to everybody this early hours of Scandinavia to dial in from there. Go to the next slide.

Here, I just want to remind everybody of our forward-looking statements. So we are familiar with the wording on that. And on that note, we will move forward. I'm very pleased to have with me today here in the room, Agnete Fredriksen, Chief Scientific Officer and Business Development; Harald Gurvin, Chief Financial Officer. And today, we also are pleased to have Martin Nicklasson, the Chairman of the Board.

And Martin, I'm going to hand over to you to kick us off for this quarterly update for third-quarter 2024.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot